May 15, 2012
Sea Lane Biotechnologies Successfully Generates and Delivers Therapeutic Candidates In Discovery Research Collaboration with Agensys, Inc., an Affiliate of Astellas Pharma Inc.
Sea Lane Biotechnologies’ Proprietary and Cutting Edge Technology Validated
MOUNTAIN VIEW, CA, MAY 15, 2012 – Sea Lane Biotechnologies, LLC, a privately-held biotherapeutic platform and product company, announced today that it has successfully completed an initial discovery research collaboration with Agensys, Inc., an Affiliate of Astellas Pharma Inc. By using its proprietary technology and world class biotherapeutic libraries, Sea Lane was able to exceed the requirements of the discovery collaboration and achieve several early stage milestones in a rapid manner. “All around, we were very pleased with Sea Lane,” says Dave Stover, Vice President of Research at Agensys.
“This collaboration validates the proprietary design and construction of our libraries against a difficult class of targets and shows the benefit over competing technologies that were compared to Sea Lane,” says Larry Horowitz, CEO of Sea Lane. This successful research collaboration, along with recent granted patents covering the technologies, provides further validation of Sea Lane’s powerful science and methods.
Sea Lane is continuing to advance their biotherapeutic platform technologies and has multiple programs in oncology progressing into human trials. In addition Sea Lane continues to pursue other research collaborations and expects to have even more positive results. For further information please contact them at info@sealanebio.com.
print page